Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-09-04
2007-09-04
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S854000, C514S853000, C514S929000, C514S930000, C530S303000, C530S308000, C530S324000
Reexamination Certificate
active
09719410
ABSTRACT:
A composition for the treatment of impaired glucose tolerance (IGT) including a compound which binds to a receptor for glucagon-like peptide-1, and a pharmaceutical carrier. The amount of the compound present is an effective amount to improve pancreatic β-cell sensitivity to blood glucose levels in a human with IGT. Also, a method for improving the pattern of insulin secretory responses in a human with IGT by administering to the human a composition comprising a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier.
REFERENCES:
patent: 6344180 (2002-02-01), Holst et al.
patent: WO97/46584 (1997-12-01), None
patent: WO98/08531 (1998-03-01), None
patent: WO98 08531 (1998-03-01), None
Rachman et al., Diabetologia, vol. 40, pp. 205-211, 1997.
Rachman J et al: “Near-normalisation of diurnal goucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.” DIABETOLOGIA, (Feb. 1997) 40 (2) 205-11., XP002122529.
Cavaghan M K et al: “Treatment with the oral antidiabetic agent troglitazone imprves beta cell responses to glucose in subjects with impaired glucose tolerance.” Journal Of Clincal Investigation, (Aug. 1, 1997) 100 (3) 530-7., XP002122530 the whole document.
Byrne M M Et Al: “Glucagon—like peptide 1 improves the ability of the beta—cell to sense and respond to glucose in subjects with impaired glucose tolerance.” DIABETEs, (Aug. 1998) 47 (8) 1259-65., XP002122530 the whole document.
D'Alessio, D. A., et al., “Elimination of the Action of Glucagon-Like Peptide-1 Causes an Impairment of Glucose Tolerance After Nutrient Ingestion by Healthy Baboons”Journal Of Clincal Investigation,(Jan. 1996) 97 (1) 133-138.
Ritzel, U., et al., “A Synthetic Glucagon-Like Peptide-1 Analog With Improved Plasma Stability”Journal Of Endocrinology,(Oct. 1998) Bristol, GB, 159 (1) 93-102.
Schirra, J., et al., “Exendin (9-39) Amide is an Antagoinist of Glucagon-Like Peptide-1 (7-36) Amide in Humans”Journal Of Clincal Investigation(Apr. 1998) 101 (7) 1421-1430.
Byrne et al., “Glucagon-Like Peptide-1 Improves the Ability of the β-Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance”,Diabetes,vol. 46, Supplement (1), p. 33A, Abstract 0127 (1997).
Byrne et al., “GLP-1 Improves First Phase Insulin Secretion without Altering Insulin Sensitivity in Subjects with Impaired Glucose Tolerance”,Diabetes,vol. 47, Supplement (1), p. A192, Abstract 0744 (1998).
Byrne & Göke, “Human Studies with Glucagon-like-peptide-1: Potential of the Gut Hormone for Clinical Use”,Diabetic Medicine,vol. 13, pp. 854-860 (1996).
Wang et al., “Glucagon-like Peptide-1 Can Reverse the Age-related Decline in Glucose Tolerance in Rats”,The Journal of Clincal Investigation,vol. 99, No. 22, pp. 2883-2889 (1997).
European Search Report published Jan. 12, 2005 in European Pat. Appl. No. 04075402.0.
Byrne—GLP-1 Improves First Phase Insulin Secretion without Altering Insulin Sensitivity in Subject with Impaired Glucose Tolerance; Diabetes; vol. 47; Abstract 0744, p. A192, (May-1998).
Byrne-Human Studies with Glucagon-like-Peptide-1: Potential of the Gut Hormone for Clincal Use; Diabetes Medicine, vol. 13; Issue 10; pp. 854-860 (Oct. 1996).
Byrne Maria
Coolidge Thomas R.
Göke Burkhard
Amylin Pharmaceuticals Inc.
Mohamed Abdel A
Tsang Cecilia J.
LandOfFree
Exendin improves β-cell response in subjects with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Exendin improves β-cell response in subjects with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Exendin improves β-cell response in subjects with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3747732